文献速递乳腺癌

TQB2102新辅助治疗HER2阳性乳腺癌II期研究

Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial.
PubMed 文献 · J Clin Oncol · 2025-11-25

该随机、开放、多中心II期研究评估双特异性HER2抗体偶联药物TQB2102新辅助治疗II-III期HER2阳性乳腺癌的疗效与安全性,共入组104例,分四个队列(每队列26例)。主要终点tpCR率分别为57.7%、76.9%、61.5%和69.2%,均优于历史对照,≥3级治疗相关不良事件发生率23.1%-30.8%,无治疗相关死亡。

要点

  • TQB2102 6.0mg/kg八周期队列tpCR率达76.9%。
  • 各队列tpCR率均显著优于40%的历史对照阈值。
  • ≥3级治疗相关不良事件发生率23.1%-30.8%,安全性可控。

核心结论

  • TQB2102在HER2阳性乳腺癌新辅助治疗中显示出稳健的抗肿瘤活性和良好的耐受性。

研究设计与样本

  • 随机、开放、多中心II期研究(NCT06198751),入组II-III期HER2阳性乳腺癌患者104例,按激素受体状态分层后1:1随机分入四个队列,每队列26例。
  • 队列1和2接受TQB2102 6.0 mg/kg每3周一次,分别6和8周期;队列3和4接受7.5 mg/kg每3周一次,分别6和8周期。
  • 主要终点为所有四个队列的总体病理完全缓解率(tpCR),若90%CI下限超过40%则认为优于历史对照。

主要发现

  • ≥3级治疗相关不良事件发生率:队列1为23.1%(6/26),队列2为30.8%(8/26),队列3为30.8%(8/26),队列4为26.9%(7/26);所有组均无治疗相关死亡。

关键数值与推荐

  • tpCR率90%CI下限超过40%为优于历史对照的阈值。
  • TQB2102剂量方案包括6.0 mg/kg和7.5 mg/kg每3周一次,周期数为6或8周期。

临床怎么用

  • TQB2102可能成为HER2阳性乳腺癌新辅助治疗的新选择,尤其8周期6.0 mg/kg方案显示较高tpCR率。
  • 治疗期间需监测≥3级治疗相关不良事件,但未发生治疗相关死亡,安全性总体可控。

局限性

  • 样本量较小,每队列仅26例,结果需更大规模研究验证。
  • 研究为开放标签设计,可能存在偏倚。
  • 随访时间短,长期生存获益尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of the bispecific human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) TQB2102 in the neoadjuvant treatment of HER2-positive breast cancer. PATIENTS AND METHODS: This randomized, open-label, multicenter, phase II study (ClinicalTrials.gov identifier: NCT06198751) enrolled HER2-positive patients with stage II and III disease. Patients were stratified by hormone receptor status and randomly assigned (1:1) to receive 6.0 mg/kg once every 3 weeks of TQB2102 for six (cohort 1) or eight cycles (cohort 2) or 7.5 mg/kg once every 3 weeks for six (cohort 3) or eight cycles (cohort 4). The primary end point was total pathologic complete response (tpCR) rate across all four cohorts (n = 26 per cohort). When the lower limit of the 90% CI (Clopper-Pearson exact binomial test) for tpCR rate exceeded 40%, efficacy was considered better than that of the historical control. RESULTS: Between February 5, 2024, and September 24, 2024, 104 patients were enrolled, with 26 patients in each cohort. The tpCR rates were 57.7% (15 of 26 [90% CI, 43.2 to 71.3]; P = .04) for cohort 1, 76.9% (20 of 26 [90% CI, 62.3 to 87.6]; P < .01) for cohort 2, 61.5% (16 of 26 [90% CI, 46.5 to 74.8]; P = .02) for cohort 3, and 69.2% (18 of 26 [90% CI, 54.6 to 81.3]; P < .01) for cohort 4. The incidence rates of grade ≥3 treatment-related adverse events were 23.1% (6 of 26) for cohort 1, 30.8% (8 of 26) for cohort 2, 30.8% (8 of 26) for cohort 3, and 26.9% (7 of 26) for cohort 4. No treatment-related deaths occurred in any groups. CONCLUSION: To our knowledge, this was the first study to report the efficacy and safety of the bispecific HER2-directed ADC TQB2102 in the neoadjuvant setting for HER2-positive breast cancer. TQB2102 showed robust activity and was well-tolerated.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li JJ, Zhang WJ, Zeng XH, et al. Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial. J Clin Oncol. 2025. PMID: 41289548. doi:10.1200/JCO-25-01153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。